| Literature DB >> 28331527 |
Berhe Beyene Gebrezgabher1, Yigzaw Kebede2, Melaku Kindie2, Desalegn Tetemke1, Mebrahtu Abay1, Yalemzewod Assefa Gelaw2.
Abstract
BACKGROUND: Adhering 95% and above of antiretroviral therapy reduces the rate of disease progression and death among people's living human immunodeficiency virus. Though manifold factors have reported as determinant factors of antiretroviral therapy adherence status, perhaps determinants of non-adherence differ up on the activities of patients in the study setting.Entities:
Keywords: Antiretroviral therapy; Case–control study; Non-adherence; Northern Ethiopia
Mesh:
Substances:
Year: 2017 PMID: 28331527 PMCID: PMC5359813 DOI: 10.1186/s12981-017-0143-1
Source DB: PubMed Journal: AIDS Res Ther ISSN: 1742-6405 Impact factor: 2.250
Socio-demographic characteristics at the time of presentation and during data collection time of cases and controls, Aksum town, northern Ethiopia 2015
| Variables | Frequency of adherence status | |
|---|---|---|
| Case, n (%) | Control, n (%) | |
| Sex | ||
| Male | 69 (50.4) | 170 (62) |
| Female | 68 (49.6) | 104 (38) |
| Age | ||
| 15–29 | 23 (16.8) | 54 (19.7) |
| 30–39 | 60 (43.8) | 127 (46.4) |
| 40–49 | 35 (25.5) | 74 (27.0) |
| ≥50 | 19 (13.9) | 19 (6.9) |
| Marital status | ||
| Single | 25 (18.2) | 47 (17.2) |
| Married | 64 (46.7) | 128 (46.7) |
| Widowed | 14 (10.2) | 32 (11.7) |
| Divorced/separated | 34 (24.8) | 67 (24.4) |
| Residence | ||
| Urban | 114 (83.2) | 253 (92.3) |
| Rural | 23 (16.8) | 21 (7.7) |
| Educational level (grade) | ||
| No formal education | 29 (21.2) | 57 (20.8) |
| Primary education (1–8) | 68 (49.6) | 128 (46.7) |
| Secondary education (9–12) | 33 (24.1) | 69 (25.2) |
| 12+ | 7 (5.1) | 20 (7.3) |
| Occupation | ||
| No occupation | 21 (15.3) | 42 (15.3) |
| Government employed | 25 (18.3) | 52 (19) |
| Business/self employed | 40 (29.2) | 96 (35) |
| Daily laborer | 51 (37.2) | 84 (30.7) |
Binary and multiple logistic regression model showing determinants of non-adherence to antiretroviral therapy, among adults on ART Aksum town, northern Ethiopia 2015
| Explanatory variables | Adherence status to ART | COR (95% CI) | AOR (95% CI) | |
|---|---|---|---|---|
| Non-adherent number (%) | Adherent number (%) | |||
| Sex | ||||
| Male | 69 (50.4) | 170 (62) | 1 | 1 |
| Female | 68 (49.6) | 104 (38) | 1.6 (1.1–2.4) | 1.4 (0.8–2.4) |
| Age | ||||
| 18–29 | 23 (16.8) | 54 (19.7) | 1 | 1 |
| 30–39 | 60 (43.8) | 127 (46.4) | 1.1 (0.6–2.0) | 1.1 (0.5–2.4) |
| 40–49 | 35 (25.5) | 74 (27) | 1.1 (0.6–2.1) | 0.7 (0.3–1.7) |
| ≥50 | 19 (13.9) | 19 (6.9) | 2.3 (1.1–5.2) | 1.7 (0.6–5.0) |
| Residence | ||||
| Urban | 114 (83.2) | 253 (92.3) | 1 | 1 |
| Rural | 23 (16.8) | 21 (76.7) | 2.4 (1.3–4.6) | 1.4 (0.5–4.0 |
| Occupation | ||||
| No occupation | 21 (15.3) | 42 (15.3) | 1 | 1 |
| Employed | 25 (18.3) | 52 (19) | 0.9 (0.5–2) | 1.4 (0.5–4.2) |
| Business | 40 (29.2) | 96 (35) | 0.8 (0.4–1.6) | 1.8 (0.7–4.0) |
| Farmer | 14 (10.2) | 10 (3.7) | 2.8 (1.1–7.4) | 2.3 (0.5–10.3) |
| Daily laborer | 37 (27) | 74 (27) | 1 (0.5–1.9) | 1.9 (0.8–4.7) |
| Duration on ART (months) | ||||
| 6–12 | 7 (5.1) | 38 (13.9) | 1 | 1 |
| 13–24 | 14 (10.2) | 38 (13.9) | 2.0 (0.7–5.5) | 2 (0.5–8.8) |
| ≥25 | 116 (84.7) | 198 (72.2) | 3.2 (1.4 7.4) | 7 (2.2,22.6)** |
| ART adverse effect | ||||
| Yes | 26 (19) | 3 (1.1) | 21.2 (6.3–71.3) | 6.9 (1.4,32.9)** |
| No | 111 (81) | 271 (98.9) | 1 | 1 |
| Substance use | ||||
| Yes | 21 (15.3) | 5 (1.8) | 9.7 (3.6–26.5) | 5.3 (1.4–20.0)* |
| No | 116 (84.7) | 269 (98.2) | 1 | 1 |
| Live with | ||||
| Alone | 33 (24.1) | 83 (30.3) | 1 | 1 |
| Parents | 18 (13.1) | 21 (7.7) | 2.2 (1.02–4.6) | 3.4 (1.2–10.3)* |
| Family | 86 (62.8) | 170 (62) | 1.3 (0.8–2.1) | 1.5 (0.8–2.8) |
| Depression status | ||||
| Depressed | 41 (29.9) | 19 (6.9) | 5.7 (3.2–10.4) | 3.3 (1.4–7.5)* |
| Not depressed | 96 (70.1) | 255 (93.1) | 1 | 1 |
| CD4 cell count (cells/mm3) | ||||
| <350 | 58 (42.3) | 45 (16.4) | 3.7 (2.4–6.0) | 3.2 (1.8–5.8)* |
| ≥350 | 79 (57.7) | 229 (83.6) | 1 | 1 |
| Dietary diversity | ||||
| Low | 57 (41.6) | 43 (15.7) | 3.8 (2.4–6.1) | 2 (1.1–3.7)* |
| Medium and above | 80 (58.4) | 231 (84.3) | 1 | 1 |
| Daily eating pattern | ||||
| ≤2 meals | 69 (50.4) | 103 (37.6) | 1.7 (1.1–2.6) | 1.01 (0.6–1.8) |
| ≥3 meals | 68 (49.6) | 171 (62.4) | 1 | 1 |
| Opportunistic infection | ||||
| Yes | 28 (20.4) | 5 (1.8) | 13.8 (5.2–36.7) | 3.6 (1–13.1) |
| No | 109 (79.6) | 269 (98.2) | 1 | 1 |
| Reminder use | ||||
| Yes | 127 (92.7) | 268 (97.8) | 0.3 (0.1–0.8) | 0.5 (0.–2.0) |
| No | 10 (7.3) | 6 (2.2) | 1 | 1 |
| Stigma | ||||
| Yes | 17 (12.4) | 10 (3.6) | 3.7 (1.7–8.4) | 2.8 (0.9–8.5) |
| No | 120 (87.6) | 264 (96.4) | 1 | 1 |
| WHO stage | ||||
| Stage I | 16 (11.7) | 68 (24.8) | 1 | 1 |
| Stage II and above | 121 (88.3) | 206 (75.2) | 2.5 (1.4–4.5) | 1.6 (0.8–3.5) |
| BMI | ||||
| Under weight | 38 (27.7) | 41 (15) | 1 | 1 |
| Normal | 97 (70.8) | 224 (81.7) | 0.5 (0.3–0.8) | 0.7 (0.3–1.3) |
| Over weight | 2 (1.5) | 9 (3.3) | 0.2 (0.1–1.2) | 0.4 (0.01–3.0) |
| Treatment other than ART | ||||
| Yes | 41 (29.9) | 40 (14.6) | 2.5 (1.5–4.1) | 1.4 (0.7–3.0) |
| No | 96 (70.1) | 234 (85.4) | 1 | 1 |
* p < 0.05
** p < 0.001